FDA Approves Jubbonti (denosumab-bddz), an Interchangeable Biosimilar to Prolia
Sandoz, has announced that the U.S. Food and Drug Administration approved Jubbonti, (denosumab-bbdz), an interchangeable biosimilar to Prolia.
Jubbonti is approved to:
• Treat postmenopausal women with osteoporosis at high risk for fracture.
• Increase bone mass in men with osteoporosis at high risk for fracture.
• Treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture.
• Increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer.
• Increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
